Desk› Healthcare› FDC Ltd

FDC Ltd

BSE 531599 FDC INE258B01022

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Filing rhythm · 60 trading days

11 filings · 3 material · busiest 2026-06-29 and 2026-08-05

What it files

SAST3 General2 Board Outcome1 Results1 Press Release1 Compliance Certificate1 Board Meeting1 Trading Window1

Filings

11 in the window

13 August 2026

General

Grant Of Marketing Authorisation From MHRA, UK For Atropine 1.0% W/V Eye Drops, Solution.

This is to inform you that the company's Subsidiary, FDC International Ltd., has received Marketing Authorisation from the MHRA, UK, for Atropine 1.0% w/v Eye Drops, Solution.

Company Update / General View filing →
5 August 2026

Board Outcome

Board Meeting Outcome for Board Meeting Outcome For Outcome For The Board Meeting Held On August 05, 2026.

Outcome for the Board Meeting Held on 5th August, 2026.

Board Meeting / Outcome of Board Meeting View filing →
5 August 2026

Results

Financial Results For The Quarter Ended June 30, 2026

Financial Results for the quarter ended June 30, 2026

Result / Financial Results View filing →
5 August 2026

Press Release

Press Release / Media Release

Press Release Q1 FY 2026-27 Results.

Company Update / Press Release / Media Release View filing →
27 July 2026

Compliance Certificate

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026

Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
23 July 2026

Board Meeting

Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday, August 05, 2026.

FDC Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting to be held ....

Board Meeting / Board Meeting View filing →
29 June 2026

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandan Mohan Chandavarkar & PACs

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
29 June 2026

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohan Anand Chandavarkar Trust (through its ....

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
29 June 2026

SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sandhya Mohan Chandavarkar Trust (through its ....

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
26 June 2026

Trading Window

Closure of Trading Window

Trading Window of the Company shall remain closed for all the Designated persons, Connected persons and their relative(s) with effect from July 01, 2026, till 48 hours after the declaration ....

Insider Trading / SAST / Closure of Trading Window View filing →
4 June 2026

General

Announcement Under Regulation 30 Of SEBI (LODR) Regulation, 2015

Announcement under Regulation 30 of SEBI (LODR) Regulation, 2015

Company Update / General View filing →